Compounds for binding proprotein convertase subtilisin/kexin type 9
US11891369B2 · kind B2 · utility
0Cited by
14References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 28, 2020 |
| Grant date | Feb 6, 2024 |
| Priority date | — |
| Expiry date | Apr 28, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/08
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity, for treatment of a disease or condition mediated, at least in part, by PCSK9. The compounds of the disclosure include compounds Formula (I).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.